- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03672773
Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer
A Phase 2 Study of Continuous Talazoparib Plus Intermittent Low-Dose Temozolomide in Patients With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer (TRIO-US L-07)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVES:
I. Evaluate the efficacy of talazoparib in combination with temozolomide as measured by objective response rate (ORR).
SECONDARY OBJECTIVES:
I. To evaluate the efficacy of talazoparib plus temozolomide as measured by progression-free survival (PFS), overall survival, duration of response, and time to response.
II. To evaluate the safety, tolerability of talazoparib plus temozolomide. III. To evaluate the pharmacokinetics of talazoparib when given in combination with temozolomide.
IV. To evaluate patient reported outcomes per the Patient Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
EXPLORATORY OBJECTIVES:
I. To identify potential biomarkers associated with response to study drug treatment.
OUTLINE:
Participants receive temozolomide orally (PO) on days 1-5 and talazoparib PO once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, participants are followed up at 30 days and then up to 1 year.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: TRIO-US IST Team
- Phone Number: 888-798-0719
- Email: ISTTeam@mednet.ucla.edu
Study Locations
-
-
California
-
Bakersfield, California, United States, 93309
- Recruiting
- CBCC Global Research, Inc. at Comprehensive Blood and Cancer Center
-
Contact:
- David Kanamori, MD
- Phone Number: 661-622-2206
-
Principal Investigator:
- David Kanamori, MD
-
Fullerton, California, United States, 92835
- Recruiting
- St. Joseph Heritage Healthcare
-
Contact:
- William E. Lawler, MD
- Phone Number: 714-446-5841
-
Principal Investigator:
- William E. Lawler, MD
-
Los Angeles, California, United States, 90095
- Recruiting
- UCLA / Jonsson Comprehensive Cancer Center
-
Contact:
- TRIO-US IST Team
- Phone Number: 888-798-0719
-
Principal Investigator:
- Jonathan W. Goldman
-
-
Florida
-
Orlando, Florida, United States, 32806
- Recruiting
- Orlando Health, Inc. d/b/a Orlando Health UF Health Center
-
Contact:
- Tirrell Tremayne Johnson, MD
- Phone Number: 401-648-3800
-
Principal Investigator:
- Tirrell Tremayne Johnson, MD
-
-
Indiana
-
Fort Wayne, Indiana, United States, 46804
- Recruiting
- Ft. Wayne Medical Oncology and Hematology, Inc.
-
Principal Investigator:
- Sunil Babu, MD
-
Contact:
- Sunil Babu, MD
- Phone Number: 260-484-8830
-
-
Kansas
-
Wichita, Kansas, United States, 67214
- Recruiting
- Cancer Center of Kansas
-
Principal Investigator:
- Shaker Dakhil, MD
-
Contact:
- Shaker Dakhil, MD
- Phone Number: 316-262-4467
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Able to provide informed consent.
- Cytologically or histologically confirmed small cell lung cancer (SCLC) with extensive-stage disease.
- Relapsed (progressed within 6 months) or refractory (progressed during or within 4 weeks of completing 1st line platinum based regimen).
- Measurable disease, as per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1.
- Archival or fresh tissue biopsy available for exploratory analyses.
- Eastern Cooperative Oncology Group (ECOG) performance status of =< 1.
- Able to swallow the study drugs, has no known intolerance to study drugs or excipients, and able to comply with study requirements.
- Female participants of childbearing potential must have a negative pregnancy test at screening and must agree to use a highly effective birth control method (defined in protocol) from the time of the first study drug treatment through 45 days after the last study drug treatment.
- Male participants must use a condom when having sex from the time of the first study drug treatment through 105 days after the last study drug treatment. Contraception should be considered for a non-pregnant female partner of childbearing potential.
- Male and female participants must agree not to donate sperm or eggs, respectively, from the first study drug treatment through 105 days and 45 days after the last study drug treatment, respectively.
- Female participants may not be breastfeeding at baseline through 45 days after the last study drug treatment.
- Absolute neutrophil count (ANC) >= 1,500/mcL
- Platelets >= 100,000/mcL
- Hemoglobin >= 9 g/dL or >= 5.6 mmol/L without transfusion or erythropoietin (EPO) dependency (within 7 days of assessment)
- Glomerular filtration rate (by Cockroft-Gault or equivalent estimation) >= 30 mL/min
- Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X ULN OR =< 5 X ULN for participants with liver metastases
- Serum total bilirubin =< 1.5 X upper limit or normal (ULN) OR direct bilirubin =< ULN for participants with total bilirubin levels > 1.5 ULN
- International normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULN unless participant is receiving anticoagulant therapy, as long as PT or partial thromboplastin time (PTT) is within therapeutic range of intended use of anticoagulants
- Activated partial thromboplastin time (aPTT) =< 1.5 X ULN unless participant is receiving anticoagulant therapy, as long as PT or PTT is within therapeutic range of intended use of anticoagulants
Exclusion Criteria:
- Has not recovered (recovery is defined as Common Terminology Criteria for Adverse Events (CTCAE) version (v)4 grade =< 1 or return to baseline) from the acute toxicities of previous therapy, except treatment-related alopecia or laboratory abnormalities otherwise meeting eligibility requirements.
- Best response of progressive disease per RECIST 1.1 to first-line platinum doublet chemotherapy.
Has received more than 1 line of cytotoxic therapy
- Prior immunotherapy and targeted therapies (including rovalpituzumab tesirine) are allowed.
- Prior treatment with a PARP inhibitor (not including iniparib) or temozolomide.
- Use of antineoplastic therapies within 14 days before study treatment initiation.
- Use of any other investigational agent within 14 days before study treatment initiation.
Received radiation therapy within 14 day before study treatment initiation (single fraction palliative radiotherapy is allowed without a washout).
- Prior thoracic irradiation and prophylactic cranial irradiation are allowed.
- Major surgery within 14 days before study treatment initiation.
- Diagnosis of myelodysplastic syndrome (MDS).
- Gastrointestinal disorder affecting absorption.
- Current or anticipated use of a prohibited P-gp inhibitor or P-gp inducer or BCRP inhibitors.
- History of another cancer within 2 years before study treatment initiation, with the exception of fully treated cancers unlikely to affect the assessment of the study treatment safety or efficacy including early stage breast, prostate, nonmelanomatous skin, thyroid, cervix and endometrial cancer.
- Any condition (concurrent disease, infection, or comorbidity) that interferes with ability to participate in the study, causes undue risk, or complicates the interpretation of safety data, in the opinion of the investigator.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (temozolomide, talazoparib)
Participants receive temozolomide PO on days 1-5 and talazoparib PO QD on days 1-28.
Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
|
Given PO
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Objective response rate defined as the proportion of participants with a confirmed complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIS)T 1.1
Time Frame: Up to 1 year
|
Will be provided along with the corresponding exact 2-sided 95% confidence interval calculated using a method based on the F distribution.
|
Up to 1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-Free Survival (PFS) assessed by RECIST 1.1
Time Frame: From treatment initiation to time of first documentation of objective tumor progression or death on study due to any cause, whichever occurs first, assessed up to 1 year
|
Will be summarized for the safety analysis (SA) set.
Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.
|
From treatment initiation to time of first documentation of objective tumor progression or death on study due to any cause, whichever occurs first, assessed up to 1 year
|
PFS assessed by RECIST 1.1
Time Frame: From treatment initiation to time of first documentation of objective tumor progression or death on study due to any cause, whichever occurs first, assessed up to 1 year
|
Will be summarized for the SA set.
Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.
Median event times and 2-sided 95% confidence interval for each median will be provided.
|
From treatment initiation to time of first documentation of objective tumor progression or death on study due to any cause, whichever occurs first, assessed up to 1 year
|
Overall survival
Time Frame: From treatment initiation to death by any cause, assessed up to 1 year
|
Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.
|
From treatment initiation to death by any cause, assessed up to 1 year
|
Duration of response (CR or PR) per RECIST 1.1
Time Frame: From the first documentation of objective tumor response, assessed up to 1 year
|
Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.
|
From the first documentation of objective tumor response, assessed up to 1 year
|
Time to response (CR or PR) per RECIST 1.1
Time Frame: From treatment initiation to the first documentation of objective tumor response, assessed up to 1 year
|
Will be summarized using the Kaplan-Meier method and displayed graphically when appropriate.
|
From treatment initiation to the first documentation of objective tumor response, assessed up to 1 year
|
Pharmacokinetics of talazoparib - steady state trough plasma concentrations
Time Frame: Up to 1 year
|
To evaluate the pharmacokinetics (steady state trough plasma concentrations) of talazoparib when given in combination with temozolomide
|
Up to 1 year
|
Collaborators and Investigators
Investigators
- Principal Investigator: Jonathan Goldman, MD, UCLA / Jonsson Comprehensive Cancer Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Carcinoma
- Small Cell Lung Carcinoma
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Antineoplastic Agents, Alkylating
- Alkylating Agents
- Poly(ADP-ribose) Polymerase Inhibitors
- Temozolomide
- Talazoparib
Other Study ID Numbers
- 18-001387
- NCI-2018-01409 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- TRIO-US L-07 (Other Identifier: UCLA / Jonsson Comprehensive Cancer Center)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Recurrent Extensive Stage Small Cell Lung Carcinoma
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingPlatinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Extensive Stage Lung Small Cell Carcinoma | Refractory Extensive Stage Lung Small Cell CarcinomaUnited States
-
National Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung CancerUnited States
-
National Cancer Institute (NCI)RecruitingExtensive Stage Lung Small Cell Carcinoma | Limited Stage Lung Small Cell Carcinoma | Platinum-Resistant Lung Small Cell Carcinoma | Platinum-Sensitive Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedStage IIIA Non-Small Cell Lung Cancer | Stage IIIB Non-Small Cell Lung Cancer | Lung Adenocarcinoma | Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer | Extensive Stage Small Cell Lung Carcinoma | Squamous Cell Lung Carcinoma | Recurrent Small Cell Lung CarcinomaUnited States
-
University of Wisconsin, MadisonNational Cancer Institute (NCI)CompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Healthy, no Evidence of Disease | Limited Stage Small Cell Lung... and other conditionsUnited States
-
Dwight OwenGenentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Extensive Stage Lung Small Cell Carcinoma | Metastatic Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
University of Colorado, DenverAriad PharmaceuticalsCompletedStage IIIA Non-small Cell Lung Cancer | Stage IIIB Non-small Cell Lung Cancer | Extensive Stage Small Cell Lung Cancer | Recurrent Small Cell Lung Cancer | Recurrent Non-small Cell Lung Cancer | Stage IV Non-small Cell Lung Cancer | Limited Stage Small Cell Lung Cancer | Adenocarcinoma of the LungUnited States
-
Zhejiang Cancer HospitalRecruitingExtensive Stage Lung Small Cell CancerChina
-
National Cancer Institute (NCI)Active, not recruitingExtensive Stage Lung Small Cell Carcinoma | Recurrent Lung Small Cell CarcinomaUnited States
-
Shanghai Yidian Pharmaceutical Technology Development...RecruitingRecurrent Extensive Stage Small Cell Lung CarcinomaChina
Clinical Trials on Temozolomide
-
Guangzhou Medical UniversityUnknownSmall Cell Lung Cancer | Metastatic CarcinomaChina
-
University of SouthamptonBristol-Myers SquibbRecruitingCancer of Esophagus | Adenocarcinoma - GEJUnited Kingdom
-
Novartis PharmaceuticalsCompletedGlioblastomaAustralia, Spain, Canada, United States
-
Activartis BiotechCompleted
-
Bradmer Pharmaceuticals Inc.Terminated
-
Peking Union Medical College HospitalBeijing Tiantan Hospital; Tianjin Medical University General HospitalUnknownMalignant GliomasChina
-
Yunpeng LiuUnknownExtensive Stage Small Cell Lung CancerChina
-
Haukeland University HospitalUniversity of Oslo; Oslo University Hospital; University Hospital of North Norway and other collaboratorsRecruiting
-
Yong-Kil HongNational Cancer Center, Korea; Samsung Medical Center; Seoul St. Mary's Hospital and other collaboratorsCompletedGlioblastomaKorea, Republic of
-
Medical University of South CarolinaTerminatedGlioma | Astrocytoma | Brain Tumor | Glioblastoma MultiformeUnited States